Revumenib
Based on 17 publication(s) in Google Scholar
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.99%
- CAS 番号: 2169919-21-3
- 分子式: C32H47FN6O4S
- 分子量:630.82
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
FDA-Approved Drug Library
HY-L022
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Blood Cancer Compound Library
HY-L079
-
Targeted Diversity Library
HY-L099
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 Revumenib
More- Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
- Blood. 2026 Feb 24:blood.2025031486. [Abstract]
- Blood. 2024 Feb 15;143(7):619-630. [Abstract]
- Nat Commun. 2025 Mar 18;16(1):2641. [Abstract]
- Leukemia. 2023 Jun;37(6):1336-1348. [Abstract]
- Cell Rep. 2025 Dec 23;44(12):116619. [Abstract]
- Int J Mol Sci. 2024 May 30;25(11):6020. [Abstract]
- Microchem J. 2025 Apr.
- Cancer Sci. 2026 May 22. [Abstract]
- iScience. 2021 Dec 25;25(1):103679. [Abstract]
- Anal Bioanal Chem. 2025 Jul;417(16):3703-3714. [Abstract]
- bioRxiv. 2026 May 26:2026.05.22.726988. [Abstract]
- Charles University. 2026.
- bioRxiv. 2025 Nov 11:2025.11.09.687496. [Abstract]
- bioRxiv. 2025 Oct 15:2025.10.13.681683. [Abstract]
- bioRxiv. 2023 Oct 1.
- University of Pennsylvania. 2022 Jan 1.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
2D/3D Cell Culture and Differentiation
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
生物活性
Menin-MLL[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2169919-21-3
-
性状 Solid
-
分子量 630.82
-
分子式 C32H47FN6O4S
-
Color White to off-white
-
SMILES
O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3
-
別名
SNDX-5613
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. [Abstract]2022 Mar 1;12(3):792-811. PMID: 34853079
Revumenib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
Relative viability of MOLM-13 cells measured after 6 days treatment of DMSO or M WM-1119, and increasing concentrations of indicated chemicals (SNDX-5613).
-
Blood
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. [Abstract]2026 Feb 24:blood.2025031486. PMID: 41734382 -
Blood
2024 Feb 15;143(7):619-630. PMID: 37890156
Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]
Primary tumors from 5 individual patients (Pt1-5) harboring a UBTF-TD alteration treated with menin inhibitor SNDX-5613 (2.5-2500 nM; 4-14 d) in vitro. Primary sample from a single patient with a RUNX1::RUNX1T1 alteration was used as a control.
Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]
MEIS1 mRNA steady-state levels in patient cells treated with SNDX-5613 (2.5-2500 nM).
Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]
CFU capacity of UBTF-TD leukemias after exposure to SNDX-5613. Cells from Pt4 and Pt5 were treated with SNDX-5613 (250 nM; 12 d) and then plated in methylcellulose.
Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]
Kaplan-Meier curves of UBTF-TD PDX model treated with vehicle or SNDX-5613 ( 75 mg/kg; p.o. twice daily (5 days on, 2 days off) for 5 weeks).
-
Nat Commun
Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. [Abstract]2025 Mar 18;16(1):2641. PMID: 40102405 -
Leukemia
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]2023 Jun;37(6):1336-1348. PMID: 36977823 -
Cell Rep
2025 Dec 23;44(12):116619. PMID: 41296561 -
Int J Mol Sci
Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. [Abstract]2024 May 30;25(11):6020. PMID: 38892207 -
-
Cancer Sci
Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL-Fusion Leukemia. [Abstract]2026 May 22. PMID: 42170936 -
iScience
2021 Dec 25;25(1):103679. PMID: 35036869 -
Anal Bioanal Chem
Dispersive solid-phase extraction as sample pretreatment for determination of chemotherapeutic agents revumenib and venetoclax by HPLC-DAD. [Abstract]2025 Jul;417(16):3703-3714. PMID: 40323377 -
bioRxiv
Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]2026 May 26:2026.05.22.726988. PMID: 42244620 -
-
bioRxiv
2025 Nov 11:2025.11.09.687496. PMID: 41292878 -
bioRxiv
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML. [Abstract]2025 Oct 15:2025.10.13.681683. PMID: 41279447 -
-
溶剤 & 溶解度
DMSO : ≥ 25 mg/mL (39.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (0.79 mM); Clear solution
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (31.70 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5852 mL | 7.9262 mL | 15.8524 mL | 39.6310 mL |
| 5 mM | 0.3170 mL | 1.5852 mL | 3.1705 mL | 7.9262 mL | |
| 10 mM | 0.1585 mL | 0.7926 mL | 1.5852 mL | 3.9631 mL | |
| 15 mM | 0.1057 mL | 0.5284 mL | 1.0568 mL | 2.6421 mL | |
| 20 mM | 0.0793 mL | 0.3963 mL | 0.7926 mL | 1.9815 mL | |
| 25 mM | 0.0634 mL | 0.3170 mL | 0.6341 mL | 1.5852 mL | |
| 30 mM | 0.0528 mL | 0.2642 mL | 0.5284 mL | 1.3210 mL |
Revumenib 関連分類
HY-136175 関連分類
Powered by Bioz